BBNX
Beta Bionics, Inc.
22.80$
+3.5%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 60.4% | 39.4% | 44.3% | 46.3% | 46.6% | 42.8% | 49.1% | 46.2% | 44.5% | 41.0% | 40.5% | 41.0% | 41.7% | |
| 39.6% | 60.6% | 55.7% | 53.7% | 53.4% | 57.2% | 50.9% | 53.8% | 55.5% | 59.0% | 59.5% | 59.0% | 58.3% | |
| 124.6% | 53.4% | 42.4% | 42.2% | 30.8% | 45.1% | 43.0% | 38.2% | 30.1% | 31.5% | 37.5% | 32.0% | 32.7% | |
| 91.4% | 40.1% | 27.2% | 30.2% | 30.6% | 23.0% | 37.5% | 33.9% | 29.1% | 26.8% | 34.8% | 30.0% | 30.0% | |
| 323.5% | 160.8% | 128.8% | 132.0% | 119.1% | 121.0% | 156.5% | 139.3% | 118.0% | 109.2% | 147.4% | 138.9% | 128.1% | |
| -283.9% | -100.2% | -73.1% | -78.3% | -65.7% | -63.8% | -105.7% | -85.5% | -62.5% | -50.2% | -87.9% | -79.9% | -69.8% | |
| – | 0.7% | – | – | – | 0.0% | – | – | – | – | – | – | – | |
| -280.6% | -225.7% | -96.3% | -96.1% | -58.3% | -88.6% | -162.5% | -72.6% | -52.1% | -41.9% | -79.3% | -73.1% | -61.3% | |
| – | – | – | – | – | – | – | – | – | 0.0% | – | – | – | |
| -280.6% | -225.7% | -96.3% | -96.1% | -58.3% | -88.6% | -162.5% | -72.6% | -52.1% | -41.9% | -79.3% | -73.1% | -61.3% | |
| -270.6% | -222.2% | -91.9% | -92.3% | -56.4% | -86.0% | -159.0% | -69.8% | -49.6% | -39.0% | -76.8% | -76.4% | -60.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.